World-first swine-flu vaccine trial reveals one dose provides 'strong immune response'

Sep 03, 2009

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

The pilot study, run by the University of Leicester and Leicester Hospitals, was trialled with 100 healthy volunteers, aged between 18 and 50.

Dr Iain Stephenson, who led the trial at the Leicester Royal Infirmary, said: "The clinical trial of MF59-adjuvanted cell-based A (H1N1) vaccine indicates that the "swine flu" vaccine elicits a strong and is well-tolerated.

"Results showed that the serum antibody responses were highest among subjects who received two doses of vaccine, however a single vaccine dose also induced responses associated with protection against influenza.

"The findings showed that it is possible to induce protective antibody against A(H1N1) infection within two weeks of administration of a single low-dose adjuvanted vaccine."

Non-adjuvanted formulations were not evaluated in this part of the study and will be evaluated shortly

The trial evaluated the tolerability and of the vaccine, and tested different schedules of vaccination, in terms of time between vaccinations. The vaccine schedule was one or two doses of 7.5μg MF-59 adjuvanted surface-antigen A/California/2009 vaccine derived from cell-culture.

Dr. Stephenson, of the Department of Infection, Immunity and Inflammation at the University of Leicester is a clinical senior lecturer at the University, and a consultant in infectious diseases at the University Hospitals of Leicester NHS Trust. He said: "The aim of the trial was to find out how many doses and what type of vaccine is needed to give protection. These initial results should help to plan vaccination campaigns in the autumn, including doses and timings. We concluded that the MF59-adjuvanted A(H1N1) vaccine of low antigen content was well tolerated and generated antibody responses associated with protection against , even after a single dose."

"The results suggest that one vaccine dose may be sufficient to protect against the A(H1N1) swine flu, rather than two. Larger trials are already underway around the world. Timings on when the vaccine will be available to governments will depend on the results of these clinical trials, and approvals by regulatory authorities''

The research found the vaccine is well tolerated with pain at the injection site the most frequent adverse event.

Additional pivotal trials with both cell culture and traditional egg based vaccines under way around the world that will include more than 6000 adults and children.

Previous research had indicated that two doses of the vaccine would be needed against swine . You can access earlier stories here:

Source: University of Leicester (news : web)

Explore further: Oregon Medicaid targets expensive hepatitis drug

add to favorites email to friend print save as pdf

Related Stories

Britain's first swine-flu trials under way

Aug 11, 2009

Britain's first swine flu vaccine trials, led by the University of Leicester and University Hospitals of Leicester NHS Trust, are taking place at the Leicester Royal Infirmary.

Scientist warns over pandemic flu vaccine 6-month time lag

Apr 27, 2009

New research published today (Monday April 27) from the University of Leicester and University Hospitals of Leicester NHS Trust warns of a six-month time lag before effective vaccines can be manufactured in the event of a ...

Single flu dose or two? Why doctors aren't sure

Sep 02, 2009

(AP) -- Why do scientists warn it may take two doses of vaccine to protect against swine flu when one dose is the norm in a regular flu season? Blame your naive immune system.

Bird flu vaccine not effective in trial

Feb 17, 2006

A highly anticipated bird flu vaccine trial in Australia has proven protective for only a small minority of the 400 volunteers in the clinical trial.

Flu season: How many shots?

Aug 30, 2009

(AP) -- Doctors don't know yet if it will take one dose or two of vaccine to protect against the new swine flu. Add that to vaccine for the regular winter flu, and it could be a multishot season for a lot of people - or ...

Recommended for you

FDA to start regulating lab-developed tests

10 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments : 0